34 results
8-K
EX-99.2
MIRM
Mirum Pharmaceuticals Inc
8 Jan 24
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
8:30am
IBAT Inhibition In Cholestatic Liver Disease Targeting IBAT Removes Circulating Bile Acids Addressing Toxic Bile Acid Accumulation Pruritus Bilirubin … -Zellweger Spectrum Disorder (PBD-ZSD) Smith-Lemli-Optiz Syndrome (SLOS) Deficiency of bile acids CDCA, CA Accumulation of toxic intermediates Progressive
8-K
EX-2.1
MIRM
Mirum Pharmaceuticals Inc
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
Water Act, the Atomic Energy Act, the Toxic Substances Control Act, the Federal Insecticide, Fungicide, and Rodenticide Act and the Clean Air Act
8-K
EX-99.2
yeqs7zxy 45br
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
424B5
9zobmuu 24g56nlcz
10 Aug 22
Prospectus supplement for primary offering
5:07pm
8-K
EX-1.1
b0z4tghuhj6wnddyanm
10 Aug 22
Other Events
12:00am
424B5
u8qdsjrcig
9 Aug 22
Prospectus supplement for primary offering
12:00am
8-K
EX-99.2
yvzf3 bph
11 Jan 22
Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones
9:00am
8-K
EX-1.1
xj5s8cirgztx6le
15 Dec 20
Other Events
5:09pm
424B5
vpvuzdcdtdgxttbimh
15 Dec 20
Prospectus supplement for primary offering
4:57pm
424B5
96ugplinxe47803w4n
14 Dec 20
Prospectus supplement for primary offering
7:13am
S-3/A
z4twy65qcvajon7hm140
10 Aug 20
Shelf registration (amended)
4:11pm
S-3
vh4evgpwim8zxwv9o
3 Aug 20
Shelf registration
9:00am
S-3
EX-1.2
0komnoj 6r4cs60
3 Aug 20
Shelf registration
9:00am
10-K
04iw jzaxha
12 Mar 20
Annual report
4:16pm
424B4
gvju9e 8f00hrcmis
9 Jan 20
Prospectus supplement with pricing info
5:11pm